Experience

OneSkin

• United States
• Biotechnology Research
• 1 - 100 Employee

• Founder and CEO

  • Mar 2016 - Present

  San Francisco OneSkin is a biotechnology company that believes in the power of data and technology to fight the oldest problem of humanity, aging. Skin aging is the fastest to test, falls in a less regulated market and moves a huge cosmetic and pharma industry. By replicating the skin aging process in vitro using diverse ethnic human skin models and integrating molecular markers we are creating a unique platform able to predict and screen new molecules, testing efficacy and safety for producing the next… Show more OneSkin is a biotechnology company that believes in the power of data and technology to fight the oldest problem of humanity, aging. Skin aging is the fastest to test, falls in a less regulated market and moves a huge cosmetic and pharma industry. By replicating the skin aging process in vitro using diverse ethnic human skin models and integrating molecular markers we are creating a unique platform able to predict and screen new molecules, testing efficacy and safety for producing the next generation of the most effective and personalized anti-aging skin products. Show less



CellSeq - in vitro and in silico solutions

• Brazil
• Biotechnology Research

• Co-founder & CEO

  • Jan 2014 - Feb 2016

  Belo Horizonte e Região, Brasil CELLSEQ solutions is a Brazilian biotechnology startup which develops tools to revolutionize the safety and toxicology assays performed by pharmaceutical, cosmetic, agrochemical and food industries with technology based on stem cells and big data analysis. Following the national and international regulatory trends, which fosters the reduction, refinement and replacement of animal experimentation, CELLSEQ produces human cells from stem cells, which exclusively provides true representation of the… Show more CELLSEQ solutions is a Brazilian biotechnology startup which develops tools to revolutionize the safety and toxicology assays performed by pharmaceutical, cosmetic, agrochemical and food industries with technology based on stem cells and big data analysis. Following the national and international regulatory trends, which fosters the reduction, refinement and replacement of animal experimentation, CELLSEQ produces human cells from stem cells, which exclusively provides true representation of the human organism. Therefore, CELLSEQ offers alternatives technologies to animal experimentation and provides much more reliable and robust data. Show less



UFMG

• Higher Education
• 700 & Above Employee

• PHD Student

  • Mar 2011 - Mar 2015

  Belo Horizonte e Região, Brasil Carolina has concluded her PhD in Biochemistry and Immunology Department at UFMG. Her project was focus with the research of pluritpotent stem cells as a source for obtaining retinal pigmented epithelium (RPE) cells in search of the best time of differentiation/maturation that favors cells to survive after transplanted on human Bruch`s membrane. She also explored the potential of the RPE-stem cells derived as toxicological model for screening of new drugs with intraocular applications.



Rugters University - Medical School of New Jersey

• PhD Exchange Student

  • Aug 2012 - Jul 2013

  Newark, NJ During her exchange student experience, Carolina worked at a laboratory of the Ophthalmology department at the Medical School of New Jersey under the supervision of Dr. Marco Zarbin. She developed project about: 1) Culture of ES cells 2) Differentiation of RPE cells-ES derived 2) Study of integrin expression on RPE-ES cells